PALO ALTO, Calif., Nov. 27, 2019 /PRNewswire/ -- Varian (NYSE:
VAR) today announced Dr. Michelle Le
Beau, professor of Medicine, University
of Chicago and director, University of Chicago Medicine
Comprehensive Cancer Center, has been appointed to the Varian Board
of Directors, effective November 27,
2019.
"We are delighted to have Michelle Le
Beau join the Varian board," said R. Andrew Eckert, chairman of Varian's Board of
Directors. "Michelle has extensive experience in cancer research,
clinical and research program development, and structure and
operation of academic cancer centers. We are excited to leverage
her strong background to advise the company as it builds the future
of multi-disciplinary cancer care solutions."
"Varian has a clear company mission and dedicated employees,"
said LeBeau. "It is an honor to join the diverse Varian Board, as
the company ushers in the era of Intelligent Cancer Care. I look
forward to being a part of the company's continued success and
expanding the access to cancer care around the world."
Dr. Le Beau holds numerous
positions at the University of Chicago,
including Arthur and Marian
Edelstein Professor of Medicine, Section of Hematology/Oncology
(1986—present); Director, University of
Chicago Medicine Comprehensive Cancer Center (2004—present);
Board Member of the University of
Chicago Medicine Cancer Council (2012—present); Director,
Cancer Cytogenetics Laboratory (1986—present).
Dr. Le Beau holds a PhD and an
M.S. in human genetics and experimental pathology from the
University of Illinois at Chicago and a
B.S. from Purdue University, and is
board-certified in clinical cytogenetics by the American Board of
Medical Genetics and Genomics.
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 locations
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/dr-michelle-le-beau-named-to-varian-board-of-directors-300966277.html
SOURCE Varian